Alpine Immune Sciences Balance Sheet Health
Financial Health criteria checks 6/6
Alpine Immune Sciences has a total shareholder equity of $332.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $373.6M and $40.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$305.66m |
| Equity | US$332.70m |
| Total liabilities | US$40.94m |
| Total assets | US$373.65m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 34LA's short term assets ($308.3M) exceed its short term liabilities ($32.2M).
Long Term Liabilities: 34LA's short term assets ($308.3M) exceed its long term liabilities ($8.7M).
Debt to Equity History and Analysis
Debt Level: 34LA is debt free.
Reducing Debt: 34LA has no debt compared to 5 years ago when its debt to equity ratio was 6.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 34LA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 34LA has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 21.4% each year.